Teona Pipiya Johnson

About Teona Pipiya Johnson

For the past 12 years, I have led the commercialization, marketing and global revenue growth of major products and portfolios for Pfizer and most recently Calliditas Therapeutics: As Head of Marketing, helped built the commercial infrastructure and strategy for Calliditas’ accelerated launch into the US market – drove product awareness and revenue growth for the first product in rare nephrology space As Global Commercial Director with Pfizer, led the worldwide commercial strategy for their $5B IBRANCE therapy, growing revenues 50% in the EU and securing its place as the #1 CDK4/6 inhibitor in the market Helped build and lead Pfizer’s US hematology franchise, launching 4 new products and growing to over $500M in revenueMy core strengths are commercialization and scientific marketing for consumer, healthcare professionals and payer audiences. I’ve built entire commercial organizations from scratch, defined global go-to-market strategies, led the launch and re-launch of billion-dollar global products and portfolios, and driven the marketing and business development organizations that have consistently created market, revenue and category leaders. I know this industry inside and out, and especially what it takes to build an organization that succeeds and grows. I’m a business strategist, a visionary marketer, a bold tactician, and throughout my leadership career I have consistently assembled and led highly engaged teams that achieve ambitious growth.MY STRENGTHS INCLUDE:Commercial Strategy/OperationsProduct CommercializationGo-to-Market & Launch StrategiesGlobal Market DevelopmentLifecycle ManagementBusiness DevelopmentPipeline DevelopmentStakeholder EngagementStrategic PartnershipsClinical Development Regulatory/Legal IssuesMy therapeutic areas of experience include oncology, hematology, pain, nephrology and rare diseases.CONTACT ME:t••••••••@gmail.com

Experience

1. Senior Vice President, Commercial

   Hansa Biopharma

   Jan 2026 — Present

   Leading US commercial strategy and launch readiness for imlifidase, Hansa Biopharma’s first US launchBuilding and scaling the US marketing and sales organization/ P&L responsibilityDriving disease strategy, positioning, and cross-functional execution across the pipeline, transplantation and immune-mediated indications

Education

• NYU Stern School of Business

  Master of Business Administration - MBA

  2006 — 2008

• Cornell University

  Biology/Genetics

  2001